The Anatomy of Addiction (21 page)

Center for Substance Abuse Treatment. (2004).
Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment improvement protocol (TIP) Series 40
(DHHS Pub. No. (SMA) 04-3939). Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

Center for Substance Abuse Treatment. (1997).
A guide to substance abuse services for primary care clinicians. Treatment improvement protocol (TIP) Series 24
(DHHS Pub. No. (SMA) 97-3139). Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

Center for Substance Abuse Treatment. (2000).
Improving substance abuse treatment: The national treatment plan initiative: Changing the conversation
(DHHS Pub No. (SMA) 00-3480, NCADI Pub No. -BKD 383). Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

Center for Substance Abuse Treatment. (2009).
Incorporating alcohol pharmacotherapies into medical practice. Treatment Improvement Protocol (TIP) Series 49.
(DHHS Pub. No. (SMA) 09-4380). Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration.

Center for Substance Abuse Treatment. (2006). “Prescription medications: Misuse, abuse, dependence, and addiction.”
Substance Abuse Treatment Advisory
5 (2): 1–4.

Center for Substance Abuse Treatment. (1994).
Screening and assessment for alcohol and other drug abuse among adults in the criminal justice system. Treatment improvement protocol (TIP) Series 7
(DHHS Pub. No. (SMA) 94-2076). Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

Center for Substance Abuse Treatment. (1998).
Substance abuse among older adults. Treatment improvement protocol (TIP) Series 26
(DHHS Pub. No. (SMA) 98-3179). Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

Center for Substance Abuse Treatment. (2005).
Substance abuse treatment for persons with co-occurring disorders. Treatment improvement protocol (TIP) Series 42
(DHHS Pub. No. (SMA) 05-3992)
.
Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (2011). “Prescription painkiller overdoses in the U.S.” Available at www.cdc.gov.

Chambers, R. A., Taylor, J. R., & Potenza, M. N. (2003). “Developmental neurocircuitry of motivation in adolescence: A critical period of addiction vulnerability.”
American Journal of Psychiatry
160(6): 1041–1052.

Cherkis, Jason. (2015, January 28) “Dying to be free—There's a treatment for heroin addiction that actually works. Why aren't we using it?”
Huffington Post
. Available at http://projects.huffingtonpost.com/dying-to-be-free-heroin-treatment.

Clark, R. E., Samnaliev, M., Baxter, J. D., & Leung, G. Y. (2011). “The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.”
Health Affairs
30 (8): 1425–433.

Comer, S. D., Sullivan, M. A., Yu, E., et al. (2006). “Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial.”
Archives of General Psychiatry
63 (2): 210–18.

Courtwright, D. T. (2001).
Dark Paradise: A History of Opiate Addiction in America
. Cambridge: Harvard University Press.

Crews, F. T., & Boettiger, C. A. (2009). “Impulsivity, frontal lobes and risk for addiction.”
Pharmacology Biochemistry and Behavior
93 (3): 237–47.

Crews, F., He, J., & Hodge, C. (2007). “Adolescent cortical development: A critical period of vulnerability for addiction.”
Pharmacology Biochemistry and Behavior
86 (2): 189–99.

Culberson, J. W., & Ziska, M. (2008). “Prescription drug misuse/abuse in the elderly.”
Geriatrics
63 (9): 22–31.

Cunningham, J. A., Sobell, L. C., Sobell, M. B., Agrawal, S., & Toneatto, T. (1993). “Barriers to treatment: Why alcohol and drug abusers delay or never seek treatment.”
Addictive Behaviors
18 (3): 347–53.

Cunningham, R. M., Harrison, S. R., McCay, M. P., et al. (2010). “National survey of emergency department alcohol screening and intervention practices.”
Annals of Emergency Medicine
55 (6): 556–62.

Curtis, J. R., Geller, G., Stokes, E. J., Levine, D. M., & Moore, R. D. (1989). “Characteristics, diagnosis, and treatment of alcoholism in elderly patients.”
Journal of the American Geriatrics Society
37 (4): 310–16.

Dackis, C. A., Lynch, K. G., Yu, E., et al. (2003). “Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study.”
Drug and Alcohol Dependence
70 (1): 29–37.

Dackis, C., & O'Brien, C. P. (2005). “Neurobiology of addiction: Treatment and public policy ramifications.”
Nature Neuroscience
8 (11): 1431–436.

Dahl, R. E. (2004). “Adolescent brain development: A period of vulnerabilities and opportunities. Keynote address.”
Annals of the New York Academy of Sciences
1021: 1–22.

Denizet-Lewis, B. (2006, June 25). “An anti-addiction pill?” Available at www.nytimes.com.

Devenyi, P., Mitwalli, A., & Graham, W. (1982). “Clonidine therapy for narcotic withdrawal.”
Canadian Medical Association Journal
127 (10): 1009–1011.

DeWit, D. J., Adlaf, E. M., Offord, D. R., & Ogborne, A. C. (2000). “Age at first alcohol use: A risk factor for the development of alcohol disorders.”
American Journal of Psychiatry
157 (5): 745–50.

Dhalla, I. A. (2011). “Facing up to the prescription opioid crisis.”
British Journal of Medicine
343 (d5142).

Dowling, G. J., Weiss, S., & Condon, T. P. (2008). “Drugs of abuse and the aging brain.”
Neuropsychopharmacology
33 (2): 209–18.

Drake, R. E., Mercer-McFadden, C., Mueser, K. T., McHugo, G. J., & Bond, G. R. (1998). “Review of integrated mental health and substance abuse treatment for patients with dual disorders.”

Drug Policy Alliance. (2009). “Healing a broken system: Veterans battling addiction and incarceration.” Available at www.phoenixhouse.org.

Druss, B. G., & Mauer, B. J. (2012). “Health care reform and care at the behavioral health–primary care interface.”
Psychiatric Services
61 (11): 1087–1092.

Dufour, M. C., Archer, L., & Gordis, E. (1992). “Alcohol and the elderly.”
Clinics in Geriatric Medicine
8 (1): 127–41.

Dupont, R. L., McLellan, A. T., Carr, G., Gendel, M., & Skipper, G. E. (2009). “How are addicted physicians treated? A national survey of physician health programs.”
Journal of Substance Abuse Treatment
37 (1): 1–7.

Elisnon, Zusha. (2015, March 16). “Aging baby boomers bring drug habits into middle age.”
Wall Street Journal
. Available at http://www.wsj.com/articles/aging-baby-boomers-bring-drug-habits-into-middle-age-1426469057.

Epstein, J., Barker, P., Vorburger, M., & Murtha, C. (2004).
Serious mental illness and its co-occurrence with substance use disorders, 2002
(DHHS Publication No. SMA 04-3905, Analytic Series A-24)
.
Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies.

Ersche, K. D., Jones, P. S., Williams, G. B., Turton, A. J., Robbins, T. W., & Bullmore, E. T. (2012). “Abnormal brain structure implicated in stimulant drug addiction.”
Science
335 (6068): 601–604.

Finlayson, R. E., Hurt, R. D., Davis, L. J., & Morse, R. M. (1988). “Alcoholism in elderly persons: A study of the psychiatric and
psychosocial features of 216 inpatients.”
Mayo Clinic Proceedings
63 (8): 761–68.

Finney, J. W., Wilbourne, P. L., & Moos, R. H. (2007). “Psychosocial treatments for substance use disorders.” In P. E. Nathan & J. M. Gorman, eds.,
A Guide to Treatments That Work
(pp. 179–202). New York: Oxford University Press.

Fiorentine, R. (1999). “After drug treatment: Are 12-step programs effective in maintaining abstinence?”
American Journal of Drug and Alcohol Abuse
25 (1): 93–116.

Fournier, M. E., & Levy, S. (2006). “Recent trends in adolescent substance use, primary care screening, and updates in treatment options.”
Current Opinions in Pediatrics
18 (4): 352–58.

Galanter, M., Dermatis, H., Glickman, L., et al. (2004). “Network therapy: Decreased secondary opioid use during buprenorphine maintenance.”
Journal of Substance Abuse Treatment
26: 313–18.

Ganju, V. (2006). “Mental health quality and accountability: The role of evidence-based practices and performance measures.”
Administration and Policy in Mental Health
33 (6): 659–65.

Glaser, Gabrielle. (April 2015). “The irrationality of Alcoholics Anonymous.”
The Atlantic
. Available at http://www.theatlantic.com/magazine/archive/2015/04/the-irrationality-of-alcoholics-anonymous/386255.

Haber, P. (2012). “Pharmacotherapies for alcohol dependence.” In E. Proude, O. Loptko, N. Lintzeris, & P. Haber, eds.,
Guidelines for the Treatment of Alcohol Problems: A Review of Evidence
(pp. 169–72). Sydney, Australia: University of Sydney.

Han, B., Gfroerer, J. C., & Colliver, J. D. (2010). “Associations between duration of illicit drug use and health conditions: Results from the 2005–2007 National Surveys on Drug Use and Health.”
Annals of Epidemiology
20 (4): 289–97.

Han, B., Gfroerer, J. C., Colliver, J. D., & Penne, M. A. (2009). “Substance use disorder among older adults in the United States in 2020.”
Addiction
104 (1): 88–96.

Hankin, J. R. (2002). “Fetal alcohol syndrome prevention research.”
Alcohol Research and Health
26 (1): 58–65.

Holder, H. D. (1998). “Cost benefits of substance abuse treatment: An overview of results from alcohol and drug abuse.”
Journal of Mental Health Policy & Economics
1 (1): 23–29.

Holloway, H. C., Hales, R. E., & Watanabe, H. K. (1984). “Recognition and treatment of acute alcohol withdrawal syndromes.”
Psychiatric Clinics of North America
7 (4): 729–43.

Hommer, D. W., Bjork, J. M., & Gilman, J. M. (2011). “Imaging brain response to reward in addictive disorders.”
Annals of the New York Academy of Sciences
1216: 50–61.

Hoof-Haines, K. V. (2012). “Dual diagnosis: The status of treating co-occurring disorders in the U.S.” Available at www.drugfree.org.

Jerrell, J. M., & Ridgely, M. S. (1995). “Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders.”
Journal of Nervous and Mental Disease
183 (9): 566–76.

Johnson, B. A. (2005). “Recent advances in the development of treatments for alcohol and cocaine dependence: Focus on topiramate and other modulators of GABA or glutamate function.”
CNS Drugs
19 (10): 873–96.

Johnson, B. A. (2008). “Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings.”
Biochemical Pharmacology
75 (1): 34–56.

Johnson, B. A., & Ait-Daoud, N. (1999). “Medications to treat alcoholism.”
Alcohol Research and Health
23 (2): 99–106.

Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000). “A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.”
New England Journal of Medicine
343 (18): 1290–297.

Jones, H. E. (2004). “Practical considerations for the clinical use of buprenorphine.”
Science and Practice Perspectives
2 (2): 4–20.

Kalivas, P. W., & Vokow, N. D. (2005). “The neural basis of addiction: A pathology of motivation and choice.”
American Journal of Psychiatry
162 (8): 1403–413.

Kampman, K. M. (2008). “The search for medications to treat stimulant dependence.”
Addiction Science and Clinical Practice
4 (2): 28–35.

Kampman, K. M., Pettinati, H., Lynch, K. G., et al. (2004). “A pilot trial of topiramate for the treatment of cocaine dependence.”
Drug and Alcohol Dependence
75 (3): 233–40.

Karila, L., Reynaud, M., Aubin, H. J., et al. (2011). “Pharmacological treatments for cocaine dependence: Is there something new?”
Current Pharmaceutical Designs
17 (14): 1359–368.

Karila, L., Weinstein, A., Aubin, H. J., Benyamina, A., Reynaud, M., & Batki, S. L. (2010). “Pharmacological approaches to methamphetamine dependence: A focused review.”
British Journal of Clinical Pharmacology
69 (6): 578–92.

Kaskutas, L. A. (2009). “Alcoholics Anonymous effectiveness: Faith meets science.”
Journal of Addictive Disorders
28 (2): 145–57.

Kelley, A. E., & Berridge, K. C. (2002). “The neuroscience of natural rewards: Relevance to addictive drugs.”
Journal of Neuroscience
22 (9): 3306–311.

Kelly, J. F., Magill, M., & Stout, R. L. (2009). “How do people recover from alcohol dependence? A systematic review of the
research on mechanisms of behavior change in Alcoholics Anonymous.”
Addiction Research and Theory
17 (3): 236–59.